DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
about
Asenapine for bipolar disorderThe State of the Art of the DSM-5 "with Mixed Features" SpecifierThe International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise AlgorithmDo Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating OverviewMixed Specifier for Bipolar Mania and Depression: Highlights of DSM-5 Changes and Implications for Diagnosis and Treatment in Primary CareCost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions.Bipolar and Depressive Disorders in Diagnostic and Statistical Manual of Mental Disorders-5: Clinical Implications of Revisions from Diagnostic and Statistical Manual of Mental Disorders-IV.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Asenapine augmentation in bipolar disorders: a case series.Suicidality and symptoms of anxiety, irritability, and agitation in patients experiencing manic episodes with depressive symptoms: a naturalistic study.Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study.Asenapine review, part II: clinical efficacy, safety and tolerability.Clinical decision making in the treatment of mixed states.The significance of mixed states in depression and mania.DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders,Treatment recommendations for DSM-5-defined mixed features.Treatment of mixed features in bipolar disorder.Treating mixed mania/hypomania: a review and synthesis of the evidence.Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials.Guidelines for the recognition and management of mixed depression.Dysphoric mania, mixed states, and mania with mixed features specifier: are we mixing things up?The Black Book of Psychotropic Dosing and Monitoring.A Review of Asenapine in the Treatment of Bipolar Disorder.Rethinking the spectrum of mood disorders: implications for diagnosis and management – Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France.
P2860
Q26775399-71B252CB-11D4-4BCF-989F-8BFFD1475FAAQ26783934-E57AB652-F828-4E53-B691-64B7A0526C87Q28066714-AF295271-DF5E-4EDE-AC7B-B7B379BB245FQ28077687-737C147E-3481-46A8-9AFA-A6D88F0F3E2BQ33975840-6E98C006-F11D-4E7A-BE16-EE411CEC3ECEQ34100578-BC58F03F-551D-4139-8F2C-922F2EE5E46DQ35042639-4C5901E3-5FDE-4D2C-8314-DD892DAB4F5EQ35123818-F6F9721F-0BD3-4EAA-8F89-60C30C58F8F6Q35862776-28AEE5AA-6F43-45E9-A74F-4940D81BC2B3Q36868401-129479A8-C5F0-4650-BE97-A575CEA300B2Q37234668-611D6EB4-6298-441B-B8A1-8477F855A03CQ37649909-EA5AC01C-AFAF-4F99-8015-B1270B905894Q38209081-B82DBF5A-597B-4AF6-A52D-EFDFF465C926Q38211511-AC151AE9-F592-4F19-9613-F65239896B1BQ38241136-1B5F9CFB-A511-46C2-BBC1-D12E8E5E6A49Q38243166-02EAA738-0F9C-4D51-9C93-6467337DB326Q38821179-9570AD2B-2FB4-4648-8A8A-BF5A4E34C966Q38952103-45A77615-2DA9-4A10-A199-53114CA6CD20Q39048607-3F189E53-EA71-435D-B2A6-6D9F5FB01006Q45912821-04A54BC2-BC05-4E85-8310-2C23DF5F39C8Q46300154-7551F6D1-989E-4B4D-A138-F4E529F669FDQ47596853-ECFB284E-E336-46BD-9AA5-E751A33EE118Q47642128-1F42AE8E-F957-4D81-9037-2EBFF18F933BQ47724110-4015203A-179F-4B87-BD8F-0B8C3A598127Q55431520-B59C0F94-C82E-4F86-B54A-762C3220D33C
P2860
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@ast
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@en
type
label
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@ast
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@en
prefLabel
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@ast
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@en
P2093
P1476
DSM-5 mixed specifier for mani ...... asenapine clinical trial data.
@en
P2093
P304
P356
10.1016/J.JAD.2013.04.025
P50
P577
2013-05-25T00:00:00Z